A medication you inject twice a year changes how people relate to treatment
Em um passo que amplia as possibilidades terapêuticas para milhões de brasileiros, a Anvisa aprovou o DENSURKO® — um medicamento injetável administrado a cada seis meses para tratar asma grave e rinossinusite crônica com pólipos nasais resistentes ao tratamento convencional. A aprovação reconhece o sofrimento de pacientes cujas condições escapam ao controle das terapias tradicionais, oferecendo uma abordagem que age sobre a raiz imunológica da inflamação, e não apenas sobre seus sintomas. O caminho regulatório foi percorrido; o caminho até o paciente ainda depende das decisões que virão.
- Pacientes com asma grave e rinossinusite crônica com pólipos vivem há anos em ciclos de inflamação, infecção e limitação que os tratamentos convencionais não conseguem romper.
- O DENSURKO® chega com uma proposta distinta: uma única injeção a cada seis meses que age diretamente sobre os eosinófilos, células imunes responsáveis pela inflamação que desencadeia crises agudas.
- A aprovação é seletiva — para asma, abrange pacientes a partir dos 12 anos com inflamação tipo 2 confirmada; para a rinossinusite, restringe-se a adultos que já esgotaram outras opções, inclusive cirurgia.
- A Anvisa abriu a porta regulatória, mas o acesso real ao medicamento ainda aguarda decisões de cobertura por parte dos sistemas público e privado de saúde.
- O impacto concreto desta aprovação será medido não pelo ato regulatório em si, mas pela velocidade e amplitude com que o medicamento chegará a quem dele necessita.
A Anvisa anunciou na quarta-feira, 13 de maio, a aprovação do DENSURKO® — nome comercial do depemoquimabe —, um medicamento injetável destinado ao tratamento de asma grave e rinossinusite crônica com pólipos nasais que não respondem às terapias convencionais. Apresentado em seringa preenchida ou caneta aplicadora, o medicamento é administrado em dose única a cada seis meses, aliviando a carga de tratamentos contínuos.
O mecanismo de ação do DENSURKO® distingue-o das abordagens tradicionais: em vez de apenas controlar os sintomas, ele atua sobre a inflamação tipo 2, reduzindo os eosinófilos — glóbulos brancos que inflamam as vias aéreas e provocam crises asmáticas severas. Para a asma, o uso foi aprovado em pacientes a partir dos 12 anos com esse perfil inflamatório específico. Para a rinossinusite crônica com pólipos, a indicação é mais restrita, limitada a adultos que não obtiveram melhora nem com tratamento clínico nem com intervenção cirúrgica.
A aprovação representa um avanço real para pessoas cujas condições comprometem o sono, a atividade física e a qualidade de vida de forma persistente. Ainda assim, o acesso efetivo ao medicamento dependerá das decisões de cobertura dos sistemas público e privado de saúde — uma etapa que determinará se essa conquista regulatória se traduzirá em benefício concreto para os pacientes elegíveis.
Brazil's health regulator gave the green light this week to a new injectable medication designed to treat two serious respiratory conditions that have long limited patients' options. The Anvisa announced on Wednesday, May 13th, that it had approved DENSURKO®, a drug containing depemoquimabe, for use against severe asthma and chronic rhinosinusitis marked by nasal polyps that resist conventional treatment.
The medication arrives as a ready-to-use injection—either in a prefilled syringe or an applicator pen—at a concentration of 100 milligrams per milliliter. Patients receive a single dose every six months, a schedule that simplifies the burden of ongoing treatment. For asthma, the drug is cleared for use in patients aged twelve and older, as well as adults, provided they have a specific type of inflammation driven by excess eosinophils—white blood cells that fuel allergic airway inflammation and can trigger severe asthma attacks. The medication works by targeting this type 2 inflammatory pathway, potentially reducing the frequency and severity of acute episodes in people whose condition has proven difficult to control.
For chronic rhinosinusitis with nasal polyps, the approval is narrower: the drug is authorized only for adults whose symptoms have not improved despite conventional therapy or surgical intervention. This restriction reflects the regulatory approach of reserving the medication for patients who have exhausted other options and face genuine clinical need.
The approval represents a meaningful expansion of the therapeutic landscape for Brazilians living with these conditions. Severe asthma and chronic rhinosinusitis with polyps can significantly degrade quality of life, limiting physical activity, disrupting sleep, and creating cycles of infection and inflammation that conventional treatments sometimes cannot break. For patients whose eosinophil counts remain elevated despite standard care, DENSURKO® offers a mechanism of action specifically designed to address the underlying immune dysfunction rather than merely managing symptoms.
What remains to be determined is how quickly and broadly the medication will reach patients through Brazil's healthcare system. Regulatory approval is one threshold; coverage decisions by public and private insurers represent another. The real-world impact of this authorization will depend on whether healthcare administrators decide to fund the drug and under what conditions—whether for all eligible patients or only those meeting additional criteria. For now, the door has opened. What happens next depends on the institutions that control access.
Citações Notáveis
The medication works by targeting type 2 inflammatory pathways, potentially reducing the frequency and severity of acute asthma episodes in people whose condition has proven difficult to control— Anvisa regulatory guidance
A Conversa do Hearth Outra perspectiva sobre a história
Why does the six-month dosing schedule matter so much for a drug like this?
Because asthma and rhinosinusitis are chronic conditions. Patients live with them for years. A medication you inject twice a year is fundamentally different from one you take daily—it changes how people relate to their treatment, whether they actually stick with it, whether they can afford the time and logistics of getting to a clinic.
And the eosinophil angle—why is that the key to understanding who this drug helps?
Eosinophils are the signature of type 2 inflammation. Not all asthma is the same. Some people have eosinophil-driven disease, some don't. This drug is a precision tool. It only works if your immune system is misbehaving in a specific way. That's why the age restriction exists too—they've tested it in kids twelve and up, not younger.
For the rhinosinusitis patients, why the requirement that they've already failed surgery?
Because surgery is invasive and expensive. If you're approving a new drug only for people who've already had surgery and still suffer, you're saying this is for the truly stuck cases. It's a way of being conservative about who gets access while still helping the people who need it most.
What's the real barrier now that Anvisa has said yes?
Money and bureaucracy. The drug exists. It's approved. But will the public health system pay for it? Will private insurers? Those are separate fights entirely. Approval is necessary but not sufficient.